Galenica Pharmaceuticals' Immune Enhancer GPI-0100 Found To be More Effective in Stimulating an Immune Response.
The paper addresses the development of novel synthetic multivalent vaccines containing different tumor-associated carbohydrate antigens, and compares the capacity of QS-21 and the related but stable and significantly less toxic GPI-0100 to enhance an antibody response. According to the authors, "The adjuvants, although related, proved significantly different, in that GPI-0100 consistently induced higher titers of antibodies than QS-21." Moreover, the authors report that, "Because GPI-0100 is less toxic than QS-21, greater quantities of GPI-0100 could be safely administered to the mice, and this resulted in a commensurate increase in antibody production."
An immune enhancer or adjuvant is a critical vaccine component that is required to stimulate a protective and/or therapeutically effective immune response against cancer cells or infectious agents. Galenica's lead adjuvant, GPI-0100, is a semi-synthetic derivative from certain natural saponins which have the capability of stimulating Th1 immunity with production of antibodies capable of mediating ADCC and of antigen-specific cytotoxic T cells (CTL) that will seek out and destroy cells carrying abnormal markers such as viral or tumor antigens. GPI-0100 is currently undergoing Phase I clinical trials at the Memorial Sloan-Kettering Cancer Center in New York, N.Y., and the University of Alabama at Birmingham Comprehensive Cancer Center in Birmingham, Ala.
Galenica Pharmaceuticals Inc. is a closely held company engaged in the development of novel products for the prevention and active immunotherapy of cancer and infectious diseases, including bioterrorism. The company's proprietary vaccine formulations integrate its immune enhancers and carriers with antigens designed using proteomic tools for optimal performance. The company's lead product, GPI-0100, has been licensed to Pfizer Inc. for use in animal vaccines, and to Endocyte, Inc. Press releases and other corporate information can be found on Galenica's website at http://www.galenicapharma.com/ .
For further information, please contact: Galenica Pharmaceuticals: David Vigor Executive Vice President (205) 982-8676 firstname.lastname@example.org
Make Your Opinion Count - Click Here http://tbutton.prnewswire.com/prn/11690X59530574
CONTACT: David Vigor, Executive Vice President of Galenica Pharmaceuticals, +1-205-982-8676, or email@example.com
Web site: http://www.galenicapharma.com/
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 21, 2002|
|Previous Article:||Lay Lake to be Lowered Beginning October 31, Reports Alabama Power.|
|Next Article:||Medline Teams With Dial to Provide Quality Skin Care Products for Health Professionals; Co-Labeled Protection Plus(R) Soaps Targeted to Health...|